Experts in Advanced High-Throughput Genetic Screening Technologies
Our valued and close partner Cellecta was founded in 2006 out of the need for higher quality, more advanced shRNA and other lentiviral libraries. The company's goal was to develop advanced high-throughput (HT) genetic screening technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.
Their genetic screening portfolio includes shRNA and CRISPR screening services, custom and off-the-shelf pooled libraries, and knockout/knockdown cell lines that facilitate genome-wide functional screening and the identification and validation of genes involved in critical biological and disease pathways.
The DriverMap Human Genome-Wide Expression Profiling Kit allows simultaneous profiling of all human protein-coding genes even from single cells in one reaction, thereby providing a reliable, accurate transcriptome profile with ultra-high sensitivity.
The DriverMap Adaptive Immune Receptor (AIR) TCR-BCR Profiling Kit is designed for profiling the CDR3 repertoire of all T-cell receptor (TCR) and B-cell receptor (BCR) chains in an single-tube, single-day assay.
With decades of experience in high-throughput functional screening, Cellecta's scientists have developed some of the most advanced technologies available in collaboration with opinion leaders and with funding from 16 NIH SBIR grants.
Although a small private company, Cellecta has partnered and published with renowned scientists and institutions, including the Roswell Park Cancer Institute, Fred Hutchinson Cancer Research Center (FHCRC), The Scripps Research Institute (TSRI), Harvard School of Public Health, Tufts University, and Health Research, Inc.